Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by DJDawg on Jan 26, 2024 3:22pm

catalysts

So the new article suggests BTD now q2. How frustrating.

So what happens with share price for the time being.

Factors
- most of us don't have that much extra cash to buy anymore than we have already so there is not likely going to be a rise from that buying
- there is thought to be another PP going on so I guess the price could bump if that is a good PP. Personally the only way I see that helping is if the PP is unexpectedly successful with a good cash raise. The only way I see that happening is if RDW has a big new buyer who is interested in getting in at a good time point. He could just invite them via the PP to join. Legal. I have no objection if it gives more runway.
- there is not a massive amount of selling at the moment so my hunch is everyone who was going to sell has sold so not sure that will push price down that much by itself (but it is TLT so could be wrong :)

Clinical factors
- GBM progress not happening with so little money. Perhaps they will announce some GBM things like a PI or MAB for that topic. Small things that make it sound like progress.
- they have done a PR run off the Jan 15 data update so the next patient updates would be CRs on the 4 patients pending for 90 days
- or could get some of the 540 day data and release it as a way of showing durable response update.
- There are 2 imminent CRs at 450 but I don't think they are going to be at 450 for a few months.

BTD factors
- maybe they get the missing BTD data faster than expected (hah) and then surprise us all with a BTD update before June (end of q2).
All in all, it feels like there is not much excitement to shift stock price for now.

Anyone else think of anything?
Comment by Mikee3003 on Jan 26, 2024 7:01pm
BTD now q2.......no surprise there. After all this leaderships consistant motto is over promise under deliver! Don't recall them ever hitting a milestone, no wonder they have a hard time raising funds! This leadership really needs to understand that under promising and over delivering will get them the respect they are after in the investment community! Tick -Tock - Tick -Tock..............
Comment by Benedictus on Jan 27, 2024 1:14am
In every interview Roger's language around the pursuit of non-dilutive financing continues to offer little hope of any near term catalyzing announcement. There's really nothing specifically proactive about being engaged with potential partners or having ongoing discussions/advanced negotiations with a potential partner, it's merely been lip service in an apparent attempt to assuage ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250